Imatinib activity on Schistosoma mansoni

Naftale Katz1,2+, Flávia Fernanda Bubulo Couto1, Neusa Araújo1

1Laboratório de Esquistossomose, Centro de Pesquisas René Rachou-Fiocruz, Belo Horizonte, MG, Brasil
2Academia Mineira de Medicina, Belo Horizonte, MG, Brasil

Imatinib, a drug used for treatment of human chronic myeloid leukaemia, due to its activity against protein kinases, has been also evaluated in vitro against Schistosoma mansoni showing high schistosomicidal activity. In the present experiments imatinib activity in vitro was confirmed at the doses of 25 µM, 50 µM and 100 µM. The first drug activity observed with the lower dose was interruption of egg-laying and with the higher dosages was the death of the worms. In mice infected with S. mansoni no activity was found even with 1,000 mg/kg/day, 500 mg/kg/day, single oral dose or when administered for three consecutive days. This is another example of the difference of results related to in vitro and in vivo trials using S. mansoni worms.

Key words: schistosomiasis - chemotherapy - imatinib

Schistosomiasis is considered by the World Health Organization the second most important endemic parasitic disease (Bruun & Aagaard-Hansen 2008). Two drugs very active against schistosomiasis mansoni, oxamniquine and praziquantel, have been used since the 1980s.

Nevertheless, praziquantel has been considered the drug of choice, since it presents activity against all the species of Schistosoma that affects humans and has a low cost, especially after being manufactured by the People’s Republic of China and South Korea.

Praziquantel is widely used with good tolerance (Katz & Almeida 2003), but experimental induction or selection of resistant strain and description of regions or patients, in cases when the compound is less active, indicate the need for alternative drugs to treat praziquantel-resistant schistosomiasis (Tsai et al. 2000, William et al. 2001, Bonesso-Sabadini & Dias 2002, Doenhoff et al. 2008, Melman et al. 2009). Qi and Cui (2013), established a new schistosomiasis model for schistosomiasis that affects humans and has a low cost, especially after being manufactured by the People’s Republic of China and South Korea.

Praziquantel is widely used with good tolerance (Katz & Almeida 2003), but experimental induction or selection of resistant strain and description of regions or patients, in cases when the compound is less active, indicate the need for alternative drugs to treat praziquantel-resistant schistosomiasis (Tsai et al. 2000, William et al. 2001, Bonesso-Sabadini & Dias 2002, Doenhoff et al. 2008, Melman et al. 2009). Qi and Cui (2013), established a new schistosomiasis model for schistosomiasis with praziquantel resistance and found that from the formula of the coexistence equilibrium is easy to see that the value of the resistant strain is increased with the value of the proportion of human with drug-resistant strain produced by treatment. This means once the proportion of human with drug-resistant strain produced by drug treatment is larger, the number of human and snails with resistant strain is larger. It must also be considered that a vaccine is not yet available (Fonseca et al. 2005) and it will take several decades before developing countries will achieve a standard of sanitation similar to that in the developed world.

Recently, it has been demonstrated that imatinib, a compound used in human chronic myeloid leukaemia therapy (Larson et al. 2008), affects Schistosoma mansoni in vitro, producing effects on gonad development, pairing stability, alterations of the gastrodermis, causing the death of the parasites. These activities of imatinib in vitro were shown to be time- and dosage-dependent and indicate that this compound must be evaluated in animal trials, as an alternative medicine for schistosomiasis (Beckmann & Grevelding 2010).

A biochemically unusual Src/Abl hybrid kinase, SmTK6, was identified in schistosomes and confirmed Abl kinases as targets for imatinib. This drug drastically affected the morphology and survival of adult schistosomes in vitro and imatinib directly acts on, at least, one of the parasites Abl kinase (SmAbl1 and on SmTK6). The Abl kinase inhibitor imatinib was able to completely block SmTK6 tyrosine kinase activity, but at a 1,000X higher concentration than that needed to inhibit SmAbl1 tyrosine kinase - induced germinal vesicle breakdown (GVBD) (Beckmann et al. 2011). Mahanty et al. (2012) look for effects following treatment of the tapeworm Taenia crassiceps in vitro and observed that imatinib and artesunate, drugs that are not traditionally considered to treat cestodes infections, showed high activity.

In our present study, imatinib was evaluated as an antischistosomal agent in trials performed in vitro (adult worms) and in vivo, using mice experimentally infected with S. mansoni.

MATERIALS AND METHODS

In vitro trials - Mice infected with S. mansoni cercaricariae (LE strain) were sacrificed using sodium pentobarbital 3% (300 µL/mice) and perfused according the technique of Smithers and Terry (1965). The collected worms were distributed into six-well-plates (4 pairs of worms/well) and were kept in culture medium RPMI-1640 supplemented with 5% foetal bovine serum, 100 µg/mL penicillin/streptomycin antibiotics. In the experimental group, the worms were exposed to the compound for 24 h and maintained in an incubator at 37°C and 5%
CO₂. In the control group, the worms were kept under the same conditions, but in the absence of the compound. Afterwards, the worms were washed with culture medium and maintained under the same previous conditions, but without compounds until the end of the trial. Observations were performed using an inverted microscope and photos were taken daily for 1-24 h until seven days after the start of the culture. The culture medium was changed on alternate days. The experiments were performed in duplicate and repeated twice.

In vivo trials - Female albino mice weighing about 20 g were infected with 100 ± 10 cercariae of S. mansoni (LE strain) by subcutaneous route. The animals were treated 45 days post-infection. Drug administration was made by gavage, with a special needle. Imatinib (Glivec®, Novartis) capsules of 400 mg were suspended in water and administered orally. The drug administration, dose and treatment period varied according to each experimental protocol. In order to analyse the drug activity, mice were sacrificed by cervical dislocation and submitted to portal-hepatic perfusion 15 days after treatment followed by worm collection from mesenteric veins and liver. The number of worms in the liver were determined by organ compression under two glass plates and counted using a stereomicroscope (Pellegrino & Siqueira 1956). Oogram was made from 1 cm of the distal part of the small intestine and eggs were classified according to the respective stages. The oogram was considered altered when one or more stages of viable eggs were absent (Pellegrino et al. 1962). In the control group, animals were infected as described, but did not receive treatment.

Activity indicators were as follows: the average number of worms, percentage distribution of worms in mesenteric veins and liver, presence of dead worms in the liver and percentage of an altered oogram when compared to the control group (Pellegrino & Katz 1968). The results obtained were compared by means of the Student’s t test, p ≥ 0.05 being stipulated as significance level.

Ethics - All experiments were carried out in accordance with Brazilian regulation on the protection of animals. Ethical approval for the study was obtained from the Ethical Committee for the use of experimental animals of the Oswaldo Cruz Foundation (CEUA L-018/09).

RESULTS

Trials performed in vitro using 25 µM showed that the intensity of movement of the worms diminished and only three dead eggs were found 72 h after the worms were removed from drug contact. With 50 µM slow movements and interruption of egg-laying were complete (Figure). At 100 µM morphological alterations and absence of egg-laying were observed. Control worms were very active with many eggs in all stages (Figure, Table I).

Imatinib used at single oral doses of 1,000 mg/kg/day, 500 mg/kg/day or 500 mg/kg/day X 3 days for treating mice was found to be inactive, based on the mean of worms recovered, distribution of the worms at the mesenteric vessels and liver. Also, no dead worms were found in the liver and no oogram alterations were observed (Table II).

DISCUSSION

Recently, it was very clearly demonstrated that imatinib, an anti-cancer compound, produces alteration of morphology, pairing stability and survival of adult S. mansoni in vitro (Beckmann & Grevelding 2010). Imatinib is a competitive antagonist of adenine triphosphate binding site, leading to inactivation of three tyrosine kinase (PDGFR, Ber-Abl and c-Kit) and interrupting downstream signalling processes (Savage & Antman 2002). Also, it has been reported that imatinib, by intra-peritoneal injection, have potent antifibrotic activity both in suppressing and reversing S. mansoni induced liver fibrosis (El-Agamy et al. 2011). When imatinib was used in vitro the results showed activity on S. mansoni with 10 µM, but alterations were intense with 50 µM or 100 µM, especially in females, but also in males. Confocal laser scanning microscopy clearly showed that the structure of the ovaries and oocytes was disordered. Also, the vitellogenin was altered in the females treated with the highest dose (100 µM). On the male worms reduction in size of the testicular lobes on spermatocytes were observed. Imatinib produces severe gastrodermis alterations in worms of both sexes (Beckmann & Grevelding 2010).

It is interesting to remark that the protein tyrosine kinases as potential targets against human schistosomiasis has been suggested by several authors (Dissous et al. 2007, Knobloch et al. 2007) against Plasmodium falciparum (Ward et al. 2004), trypanosomes and Leishmania (Naula et al. 2005) and Echinococcus multilocularis larvae (Hemer & Brehm 2012). Several compounds that are protein kinase inhibitors have been approved for cancer treatment in humans (Cohen 2009).

Our present results are in accordance with Beckmann and Grevelding (2010) as far as in vitro activity is concerned. We used only optical microscopy for assessing the decrease in movements, worm separation of couples and stop of egg-laying, starting with imatinib at the dose of 25 µM, being more active at 50 µM and 100 µM.
The interruption of egg-laying in vitro is a phenomenon that has been observed with other active compounds and can be considered an important sign for detecting anti-schistosomal activity. It is interesting to remark that also in vivo, in mice experimentally infected with *S. mansoni* or *Schistosoma japonicum*, the oogram method, which is the description of different egg stages found at the intestinal wall, has been used for drug screening since 1960s (Pellegrino et al. 1962).

When imatinib was orally administered to mice experimentally infected with *S. mansoni*, with the protocol followed in this study, no activity was detected, even at the doses of 1,000 mg/kg or 500 mg/kg that can be considered very high, when compared to the active dose used for treatment of clinical cases of myeloma leukaemia that is 400 mg per day. Kretz et al. (2004) found that the mean fraction of imatinib in plasma (f<sub>p</sub>) was 50% in mouse and up to 92% in acute lymphatic leukaemia (AML) patients. Similarly, f<sub>p</sub> for CGP74588, the primary metabolite of imatinib, was 70% in mouse and 90% in some AML patients. The failure of imatinib treatment cannot yet be explained, since the dosage of imatinib administered was very high, over 50 times higher than the clinical dose for daily treatment. Again, the discrepancy between the results obtained when comparing anti-schistosomal agents in vitro and in vivo has already been described (Araújo et al. 2008). Although in vitro studies are useful to generate knowledge, they are obviously limited. A medication may change depending on the specific biological processes of the organism. In vitro experiments are a simulation of the reality and they must be tied to in vivo studies, to support scientific research (Andersen et al. 2004).

**ACKNOWLEDGEMENTS**

To Dr John R Kusel, for reviewing the manuscript, to Dr Roberto Porto Fonseca, for providing the Glivec for conducting this study, and to Vera de Paula Ribeiro, for english assistance.

**REFERENCES**

Andersen ML, D’Almeida Vânia, Gui Mi KO, Kawakami R, Martins PIF, Magalhães L, Tufik S 2004. *Princípios éticos e práticos do uso de animais de experimentação*, CLR Balieiro, São Paulo, 167 pp.
Araújo N, de Mattos ACA, Coelho PMZ, Katz N 2008. Association of oxamnique, praziquantel and clonazepam in the experimental schistosomiasis mansoni. *Mem Inst Oswaldo Cruz* 103: 781-785.

Beckmann S, Grevedeling CG 2010. Imatinib has a fatal impact on morphology, pairing stability and survival of adult *Schistosoma mansoni* in vitro. *Int J Parasitol* 40: 521-526.

Beckmann S, Hahnel S, Cailliou K, Vanderstraet M, Browaeys E, Dissous C, Grevedeling CG 2011. Characterization of the Src/Abl hybrid kinase SmTK6 of *Schistosoma mansoni*. *J Biol Chem* 286: 42325-42336.

Bonesso-Sabadini PIP, Dias LCS 2002. Altered response of *Schistosoma mansoni* to oxamnique and praziquantel. *Mem Inst Oswaldo Cruz* 97: 381-385.

Bruun B, Aagaard-Hansen J 2008. *The social context of schistosomiasis and its control: an introduction and annotated bibliography*, World Health Organization, Geneva, 213 pp.

Cohen P 2009. Targeting protein kinases for the development of anti-inflammatory drugs. *Curr Opin Cell Biol* 21: 317-324.

Dissous C, Ahier A, Khayath N 2007. Protein tyrosine kinases as new potential targets against human schistosomiasis. *Byoessays* 29: 281-288.

Doenhoff MJ, Cioli D, Utzinger J 2008. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. *Curr Opin Infect Dis* 21: 659-667.

El-Agamy DS, Shebl AM, Said AS 2011. Prevention and treatment of *Schistosoma mansoni*-induced liver fibrosis in mice. *Inflammopharmacology* 19: 307-316.

Fonseca CT, Cunha-Neto E, Goldberg AC, Kalil J, Jesus AR, Carvalho EM, Correa-Oliveira R, Oliveira SC 2005. Human T cell epitope mapping of the *Schistosoma mansoni* 14kDa fatty acid-binding protein using cells from patients living in areas endemic for schistosomiasis. *Microbes Infect* 7: 204-212.

Hemer S, Brehm K 2012. In vitro efficacy of the anticancer drug imatinib on *Echinococcus multilocularis* larvae. *Int J Antimicrob Agents* 40: 458-462.

Katz N, Almeida K 2003. Esquistossomose, xistosa, barriga d’água. *Ciênc Cult* 55: 38-43.

Knobloch J, Beckmann S, Burmeister C, Quack T, Grevedeling CG 2007. Tyrosine kinase and cooperative TGF beta signaling in the reproductive organs of *Schistosoma mansoni*. *Exp Parasitol* 117: 318-336.

Kretz O, Weiss MH, Schumacher MM, Gross G 2004. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. *Br J Clin Pharmacol* 2: 212-216.

Larson RA, Druker BJ, Guilhot F, O’Brien SG, Riviere GJ, Krahnecke T, Gathmann I, Wang Y 2008. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. *Blood* 111: 4022-4028.

Mahanta S, Madrid EM, Nash TE 2012. Quantitative screening for antischistode drugs based on changes in baseline enzyme secretion by *Taenia crassiceps*. *Antimicrob Agents Chemother* 57: 990-995.

Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, Mutuku MW, Karanja DMS, Colley DG, Black CL, Secor WE, Mkoji GM, Loker ES 2009. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of *Schistosoma mansoni*. *PLoS NTDi* 3: e504.

Naula C, Parsons M, Mottram JC 2005. Protein kinases as drugs targets in trypanosomes and *Leishmania*. *Biochim Biophys Acta* 1754: 151-159.

Pellegrino J, Katz N 1968. Experimental chemotherapy of schistosomiasis mansoni. *Adv Parasitol* 6: 233-290.

Pellegrino J, Oliveira CA, Faria J, Cunha AS 1962. New approach to the screening of drugs in experimental *Schistosoma mansoni* in mice. *Am J Trop Med Hyg* 11: 201-215.

Pellegrino J, Siqueira AF 1956. Técnica de perfusão para colheita de coelhice de *Schistosoma mansoni* em cobaias experimentalmente infectadas. *Rev Bras Malariol* 8: 589-597.

Qi L, Cui J 2013. A schistosomiasis model with praziquantel resistance. *Discrete Dynamics in Nature and Society* 2013: ID 945767.

Savage DG, Antman KH 2002. Imatinib mesylate: a new oral targeted inflammatory drugs. *N Engl J Med* 346: 683-693.

Smithers SR, Terry RJ 1965. The infection of laboratory hosts with cercariae of *Schistosoma mansoni* and the recovery of adult worms. *Parasitology* 55: 695-700.

Tsai MH, Marx KA, Ismail MM, Tao LF 2000. Randomly amplified polymorphic DNA (RAPD) polymerase chain reaction assay for identification of *Schistosoma mansoni* strains sensitive or tolerant to anti-schistosomal drugs. *J Parasitol* 86: 146-149.

Ward P, Equinet L, Packer J, Doerig C 2004. Protein kinases of the human malaria parasite *Plasmodium falciparum*: the kinome of a divergent eukaryote. *BM C Genomics* 5: 79.

William S, Sabra A, Ramzy F, Mousa M, Demerdash Z, Bennett JL, Day TA, Botros S 2001. Stability and reproductive fitness of *Schistosoma mansoni* isolates with decreased sensitivity to praziquantel. *Int J Parasitol* 31: 1093-100.